Sulphonamine compounds and methods of making and using same
US-9221787-B2 · Dec 29, 2015 · US
N-benzylindole modulators of PPARG
US9051265B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9051265-B2 |
| Application number | US-201213490342-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 6, 2012 |
| Priority date | Jun 6, 2011 |
| Publication date | Jun 9, 2015 |
| Grant date | Jun 9, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A non-agonist peroxisome proliferator active receptor gamma (PPARG) modulatory compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R is H, (C 1 -C 6 )alkyl, (C 3 -C 9 )cycloalkyl, or (C 1 -C 6 )haloalkyl; R′ is independently H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, or (C 3 -C 9 )cycloalkyl; each X is independentl…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9051265B2 cover?
- The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes…
- Who is the assignee on this patent?
- Kamenecka Theodore Mark, Griffin Patrick R, Koenig Marcel, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07D209/42. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).